Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
The Korean Journal of Hepatology ; : 120-129, 2011.
Article in English | WPRIM | ID: wpr-172642

ABSTRACT

BACKGROUND/AIMS: Combination treatment consisting of hepatic arterial infusion chemotherapy with epirubicin and cisplatin (HAIC-EC) and systemic infusion of low-dose 5-fluorouracil (5-FU) are sometimes effective against advanced hepatocellular carcinoma (HCC). However, there is no effective treatment for advanced HCCs with arterioportal shunts (APS) or arteriovenous shunts (AVS). METHODS: We investigated a response and adverse events of a new combination protocol of repeated HAIC-EC and percutaneous intratumoral injection chemotherapy with a mixture of recombinant interferon-gamma (IFN-gamma) and 5-FU (PIC-IF) in patients with far-advanced HCCs with large APSs or AVSs. RESULTS: There was a complete response (CR) for the large vascular shunts in all three patients and for all tumor burdens in two patients. Significant side effects were flu-like symptoms (grade 2) and bone marrow suppression (grade 2 or 3) after each cycle, but these were well-tolerated. CONCLUSIONS: These results suggest that the combination of HAIC-EC and PIC-IF is a new and promising approach for advanced HCC accompanied by a large APS or AVS.


Subject(s)
Aged , Humans , Male , Angiography , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Hepatocellular/drug therapy , Cisplatin/administration & dosage , Epirubicin/administration & dosage , Fluorouracil/administration & dosage , Hepatic Artery , Infusions, Intra-Arterial , Injections, Intramuscular , Interferon-gamma/administration & dosage , Liver Neoplasms/drug therapy , Tomography, X-Ray Computed , Tumor Burden
2.
Journal of Korean Medical Science ; : 167-171, 2004.
Article in English | WPRIM | ID: wpr-67710

ABSTRACT

The aim of this study was to investigate the adjuvant effects of interferon-gamma (IFN-gamma) inhalation therapy for six months in the treatment of refractory multidrug-resistant pulmonary tuberculosis (MDR-TB). Aerosolized IFN-gamma was given to six MDRTB patients with persistent positive smears and cultures despite long-term medical treatment. The patients received aerosolized two million international units of IFNthree times a week for 6 months while they continued on identical antituberculous chemotherapy. Before IFN-gamma inhalation therapy, the patients received a median of 6.5 (range, 4 to 7) antituberculous drugs for median duration of 29 months (range,7 to 76). After IFN-gamma inhalation therapy, sputum smears remained persistently positive in all patients throughout the study period. Sputum cultures were transiently negative at the 4th month in two patients, but became positive again at the end of 6 months of IFN-gamma therapy. Five patients had radiological improvement including three patients who showed a decrease in the size of the cavitary lesions. Resectional surgery could be performed in one patient in whom substantial clinical and radiological improvement was noted after IFN-gamma inhalation therapy. These results suggest that IFN-gamma inhalation therapy may be effective for some cases of refractory MDR-TB who are otherwise not responding to conventional therapy.


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Administration, Inhalation , Antineoplastic Agents/administration & dosage , Antitubercular Agents/therapeutic use , Drug Resistance, Bacterial , Drug Resistance, Multiple , Drug Therapy, Combination , Interferon-gamma/administration & dosage , Tuberculosis, Pulmonary/drug therapy
3.
Rev. obstet. ginecol. Venezuela ; 60(3): 161-4, sept. 2000.
Article in Spanish | LILACS | ID: lil-278878

ABSTRACT

Investigar las concentraciones de interferón-gamma en sueros de pacientes con preeclampsia. Cátedra de inmunología. Departamento de Ciencias Fisiológicas. Estudio prospectivo en 30 pacientes con preeclampsia y 30 controles con embarazo no complicado en tercer trimestre. Cuantificación de la citotina con inmunoanálisis enzimático de doble anticuerpo. Cifras elevadas en preeclampsia. Diferencia significativa con el control. El interferón-gamma, como otras citocinas de fenotipo Thl, parece estar involucrado en la patogenia de la preeclampsia


Subject(s)
Humans , Female , Pregnancy , Adult , Pre-Eclampsia/diagnosis , Pre-Eclampsia/therapy , Interferon-gamma/administration & dosage , Venezuela , Gynecology , Obstetrics
4.
Arch. argent. dermatol ; 47(2): 53-66, mar.-abr. 1997. ilus
Article in Spanish | LILACS | ID: lil-196996

ABSTRACT

La leshmaniasis es producida por un protozoo, trasmitida por muchos mosquitos hematófagos (Lutzomia brasiliensis), artrópodos (Rhipicephalus turanicus) y probablemente triatomideos (Triatoma infestans, Pansterongilus infestans). En Bolivia existen tres formas de leishmaniasis: cutánea, mucocutánea y visceral, producidas por el mismo agente etiológico, con tres diferentes fases evolutivas relacionadas con mecanismos inmunológicos dependientes de muchos factores. Las tres responden a diversas drogas, a veces inespecíficas, que son empleadas para otras enfermedades (plasmodios, trichomonas, giardias, hongos y bacilos de Koch). Las sales antimoniales pentavalentes son las más comúnmente usadas, con resultados variables, a veces adversos, por su toxicidad, ineficacia ineficiencia y, sobre todo, resistencia y difícil manejo. Se ha demostrado que la L. cutánea tratada con glucantime, anfotericina B y otros presenta posteriormente lesiones mucocutáneas. Por otro lado, leishmaniosos que curaron espontáneamente han mostrado lesiones secundarias en forma ocasional. Lo que demuestra que en esta enfermedad existe una falla inmunológica, razón por la que usamos un inmunomodulador (DECARIS-clorhidrato de levamisol-, que es un antiparasitario), con buenos resultados (95 por ciento de éxito), sobre todo por su bajo costo, uso cómodo y efectos colaterales mínimos. Finalmente concluimos que en el momento actual no existe un leishmanicida eficaz para el tratamiento de esta enfermedad. El tratamiento inmunológico parece ser muy prometedor


Subject(s)
Humans , Allopurinol/therapeutic use , Antimony Sodium Gluconate/therapeutic use , Leishmaniasis, Cutaneous/drug therapy , Leishmaniasis, Mucocutaneous/drug therapy , Leishmaniasis/drug therapy , Levamisole/therapeutic use , Allopurinol/administration & dosage , Antimony Sodium Gluconate/administration & dosage , Antimony Sodium Gluconate/adverse effects , Antiparasitic Agents/therapeutic use , Bolivia/epidemiology , Diagnosis, Differential , Disease Vectors/classification , Interferon-gamma/administration & dosage , Interferon-gamma/therapeutic use , Itraconazole/administration & dosage , Itraconazole/therapeutic use , Leishmaniasis, Cutaneous/diagnosis , Leishmaniasis, Cutaneous/immunology , Leishmaniasis, Mucocutaneous/diagnosis , Leishmaniasis, Mucocutaneous/immunology , Leishmaniasis/pathology , Leishmaniasis/transmission , Leishmania/classification , Levamisole/administration & dosage , Metronidazole/administration & dosage , Metronidazole/therapeutic use
5.
Prensa méd. argent ; 73(16): 698-700, 17 oct. 1986.
Article in Spanish | LILACS | ID: lil-45742

ABSTRACT

La varicela, primoinfección del HVZ, al curarse, dejaría acantonados los virus en estado de latencia, preferentemente en los ganglios raquídeos, que al reactivarse provocarían el herpes zoster (zona) o el varicella zoster atípico. La reactivación se produce preferentemente en pacientes con disminución de la inmunidad celular. Las complicaciones más graves por su porcentaje de mortalidad son la encefalitis y encefalomielitis, sin embargo se enfocan desde el punto de vista etiopatogénico y terapéutico a las algias postzonatosas (del tipo de desaferentación) dadas su frecuente presentación, importancia clínica y rebeldía terapéutica. Se puede encarar la terapéutica seccionando la vía de la nocicepción en la forma más selectiva posible, es decir respetando la vía lemniscal, por medio de dos métodos: uno químico y el otro neuroquirúrgico


Subject(s)
Humans , Chickenpox/complications , Encephalitis/etiology , Encephalomyelitis/etiology , Herpes Zoster/complications , Herpesvirus 3, Human/immunology , Immunity, Cellular , Interferon-gamma/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL